Recruiting

Mother-Infant Cohort Study in Malaysia and China

This mother-infant cohort study aims to determine the geographic differences in the microbial profiles in breast milk from mothers living in Malaysia and China that are potentially important determinants of infant development. It also aims to determine the impact of gut microbiome on infant health (temperament, gastrointestinal symptoms, eczema symptoms, and asthma symptoms).

ClinicalTrials.gov IDNCT04919265

PhaseNot Applicable

Enrollment200

SponsorUniversiti Putra Malaysia

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Gut Microbiota, Gastrointestinal Symptoms, Temperament, Eczema, Asthma, Breast Milk Collection

About this study

Interventions

Other: No intervention - mother-infant cohort study — There are no interventions because it is a mother-infant cohort study

Primary outcomes

Breastmilk microbiome (from birth to 12 months)
Gut microbiome (from birth to 12 months)

Eligibility information

Inclusion Criteria: * Pregnant women aged between 18 and 45 years old * Pregnant women who attend the antenatal check-up at the selected clinics/hospitals * Pregnant women with the gestational age of less than 12 weeks * Pregnant women who plan to attend post-natal check-ups for at least one year at the same clinic/hospital Exclusion Criteria: * Pregnant women who are diagnosed with immune deficiency * Pregnant women who have a multiple pregnancy and preterm delivery (\<37 weeks) * Pregnant women who plan to move out of the study area in the next one year * Pregnant women with fetal/newborn with congenital abnormalities

Study locations

Private hospital, Kajang, Selangor 43000 Malaysia

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.